Castor Oil for Fatty Liver: What the Evidence Shows

How to use castor oil for fatty liver is a question that circulates widely online, but the honest answer is that you should not. There is no clinical evidence that castor oil, whether taken orally or applied as a topical pack, reduces liver fat, improves liver function tests, or slows the progression of fatty liver disease. UK guidelines from NICE and the British Society of Gastroenterology make no mention of castor oil as a treatment. This article explains what the evidence actually shows, how fatty liver disease is managed in the UK, the real risks of castor oil, and which lifestyle changes are proven to help.

Does castor oil actually help with fatty liver disease?

Castor oil does not help with fatty liver disease. No peer-reviewed human evidence supports its use, and it is not recommended by NICE or the British Society of Gastroenterology.

There is no credible clinical evidence that castor oil helps with fatty liver disease, and it is not recommended by UK clinical guidelines, including those from NICE and the British Society of Gastroenterology (BSG). Fatty liver disease, known medically as metabolic dysfunction-associated steatotic liver disease (MASLD) or, in its alcohol-related form, alcohol-related liver disease (ALD), is a well-characterised condition with established, evidence-based management pathways. You may also see the older terms NAFLD (non-alcoholic fatty liver disease) and MASH (metabolic dysfunction-associated steatohepatitis) in NHS documents and letters, as these are still in use during the transition to updated terminology.

Castor oil is a vegetable oil derived from the seeds of Ricinus communis.^[14] It has a long history of folk use as a laxative and topical remedy, but its proposed benefits for liver health are not supported by human clinical trial data.

Some proponents suggest applying castor oil as a warm compress over the abdomen (sometimes called a "castor oil pack") to support liver detoxification. However, the concept of "detoxifying" the liver through topical application has no basis in peer-reviewed human research. The liver is the body's primary detoxification organ and performs this function continuously without external assistance. There is no published evidence from human studies that castor oil, applied topically or taken orally, alters liver fat content, reduces liver inflammation, or improves liver function tests.

If you have been diagnosed with fatty liver disease, or are concerned about your liver health, it is important to speak with your GP rather than relying on unproven remedies. Early intervention with evidence-based strategies can prevent progression to more serious conditions such as liver fibrosis or cirrhosis.

What does the evidence say about castor oil and liver health?

No randomised controlled trials or systematic reviews in humans show that castor oil reduces liver fat or improves liver enzymes. Animal data on ricinoleic acid has not been replicated in human liver disease trials.

The available evidence does not support the use of castor oil as a treatment for fatty liver disease in humans. No randomised controlled trials, systematic reviews, or observational studies in humans have demonstrated that castor oil reduces hepatic steatosis (fat accumulation in the liver), improves liver enzyme levels, or slows disease progression in people with MASLD or ALD.

Some animal studies have examined ricinoleic acid, the principal fatty acid in castor oil, for anti-inflammatory properties. However, findings from animal models do not translate reliably to human clinical outcomes, and no human trials have followed up these preliminary observations in the context of liver disease. The broader category of "liver detox" products, of which castor oil packs are a part, has similarly not demonstrated clinical benefit in peer-reviewed human research.

By contrast, there is a substantial and growing body of evidence supporting lifestyle-based interventions for MASLD. Weight reduction of 7 to 10 per cent of body weight has been shown in multiple trials to significantly reduce liver fat and inflammation, and this forms the basis of current NICE and BSG guidance on MASLD management. When evaluating any remedy for a chronic condition such as fatty liver disease, it is important to distinguish between anecdotal reports and peer-reviewed clinical evidence. Relying on unproven treatments may delay access to interventions that have a genuine, documented benefit.

How do doctors in the UK treat fatty liver disease?

UK doctors treat MASLD primarily with sustained lifestyle modification, including diet and exercise, supported by non-invasive fibrosis assessment tools and, where appropriate, pharmacological options such as resmetirom.

UK doctors manage fatty liver disease primarily through lifestyle modification, with pharmacological treatment reserved for specific circumstances and guided by NICE recommendations. The cornerstone of management for MASLD is sustained weight loss, achieved through a combination of dietary change and increased physical activity. NICE guidance recommends gradual, sustained weight reduction; rapid weight loss can paradoxically worsen liver inflammation and should be avoided.^[18]

In terms of investigation, a GP will typically arrange blood tests including liver function tests and a fasting lipid and glucose profile. Liver ultrasound is commonly used to detect steatosis, though it does not reliably stage fibrosis. Where significant fibrosis is suspected, non-invasive scoring tools such as the FIB-4 index or the enhanced liver fibrosis (ELF) test (which has NICE diagnostics guidance supporting its use in primary care triage) may be used before considering referral to hepatology. Liver elastography may also be used to assess fibrosis non-invasively. A liver biopsy may be recommended in selected cases to stage fibrosis accurately.

Pharmacological options are evolving. Resmetirom (Rezdiffra) received a marketing authorisation in the UK for adults with non-cirrhotic MASLD with moderate to advanced liver fibrosis.^[3][4] Patients and clinicians should note that NHS availability depends on local commissioning decisions by Integrated Care Boards (ICBs) and any relevant NICE technology appraisal, which may differ from the marketing authorisation alone. Vitamin E supplementation has been used in some non-diabetic patients with biopsy-proven metabolic dysfunction-associated steatohepatitis (MASH), though this is not universally recommended, carries potential risks, and should only be considered under specialist supervision.^[19] Management of associated conditions, including type 2 diabetes, hypertension, and dyslipidaemia, is also central to reducing liver disease progression. Alcohol-related liver disease requires complete alcohol cessation, supported by structured programmes where appropriate.

If you experience symptoms that may indicate significant liver disease, including jaundice (yellowing of the skin or eyes), swelling of the abdomen, vomiting blood or passing black stools, confusion, or severe pain in the upper right abdomen with fever, seek urgent medical attention or call 999 or NHS 111.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online consultations, with prescriber review and pharmacist support, for those seeking guidance on weight management as part of a broader health plan.

Are there any risks or side effects of taking castor oil?

Oral castor oil can cause severe diarrhoea, hypokalaemia, and electrolyte disturbances, and must not be used in pregnancy, bowel obstruction, or by anyone on digoxin or potassium-sensitive medicines.

Taking castor oil orally carries genuine risks, particularly when used in large quantities or over a prolonged period, and these risks are relevant to anyone considering it as a self-treatment for fatty liver disease. Castor oil is a potent stimulant laxative. Even in small doses, it can cause:

• Severe diarrhoea and abdominal cramping, which can lead to dehydration and electrolyte imbalance

• Nausea and vomiting

• Dizziness and weakness, particularly in older adults or those with existing health conditions

• Electrolyte disturbances, including low potassium (hypokalaemia), which can affect heart rhythm

Chronic or repeated use of stimulant laxatives, including castor oil, can cause laxative dependency and may impair normal bowel function over time. In people with liver disease, electrolyte disturbances carry additional risk given the liver's central role in metabolic regulation. Dehydration can also temporarily worsen liver function test results.

Castor oil should not be taken orally during pregnancy. It has uterotonic (uterus-stimulating) effects and has historically been used to induce labour; use during pregnancy carries a risk of premature or unwanted uterine contractions. Anyone who is pregnant, trying to conceive, or breastfeeding should seek medical advice before using castor oil in any form.

Castor oil should not be given to children without medical advice.

Castor oil should not be taken orally by anyone with bowel obstruction, symptoms of an acute abdomen (such as severe abdominal pain that may indicate appendicitis), or a flare of inflammatory bowel disease. It should also be avoided in anyone who is already severely dehydrated or has significant electrolyte imbalance.

Because castor oil can cause hypokalaemia, it may interact with medicines that are sensitive to potassium levels, including digoxin and certain diuretics and anti-arrhythmic medicines. If you take any regular medicines, speak to your pharmacist or GP before using castor oil. The BNF lists relevant cautions and interactions for stimulant laxatives.

Topical castor oil packs are generally considered lower risk, but they are not without potential for skin irritation or allergic reaction in sensitive individuals. There is also a risk of harm through delayed treatment: if someone relies on castor oil instead of seeking medical advice, the underlying liver condition may progress undetected.

If you experience any unexpected symptoms after taking castor oil, including severe abdominal pain, persistent vomiting, or signs of dehydration, contact NHS 111 for urgent advice. Any suspected adverse reaction to a product can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

What lifestyle changes can genuinely improve a fatty liver?

A Mediterranean-style diet, 150 minutes of moderate aerobic activity per week, and 7 to 10 per cent weight loss are the most effective evidence-based interventions for improving fatty liver disease.

Sustained lifestyle modification is the most effective intervention for improving fatty liver disease, and the evidence supporting this is robust across multiple clinical trials. The following changes are recommended within UK clinical practice and are consistent with NICE guidance and BSG recommendations:

Diet:

• Reduce overall calorie intake to achieve gradual weight loss of around 0.5 to 1 kg per week, in line with NHS weight management guidance

• Follow a Mediterranean-style diet, which is rich in vegetables, legumes, whole grains, fish, and olive oil, and low in processed foods, refined sugars, and saturated fats; this dietary pattern has evidence of benefit in MASLD^[20][21]

• Limit or eliminate alcohol; even in MASLD where alcohol is not the primary cause, alcohol intake can worsen liver inflammation, and UK clinical guidance for people with liver disease generally recommends keeping within or below the UK Chief Medical Officers' low-risk guidelines of no more than 14 units per week, or abstaining entirely if advised by your clinician^[9][10]

• Reduce consumption of ultra-processed foods and sugar-sweetened beverages, including fruit juices

Physical activity:

• Aim for at least 150 minutes of moderate-intensity aerobic activity per week, consistent with the UK Chief Medical Officers' Physical Activity Guidelines

• Resistance (strength) training has also been shown in clinical studies to reduce liver fat, including independently of weight loss, and is a valuable addition to an aerobic programme^[22]

• Even modest increases in activity, such as brisk walking, can produce measurable improvements in liver fat content

Weight management:

• A weight reduction of 7 to 10 per cent of body weight is associated with significant reductions in liver fat and inflammation, as supported by NICE and BSG guidance

• For people with obesity and MASLD, structured weight management programmes, and in some cases pharmacological support for weight loss, may be appropriate following assessment by a clinician

Other factors:

• Managing type 2 diabetes, high blood pressure, and raised cholesterol reduces the overall burden on the liver

• Regular monitoring through your GP allows early detection of disease progression

These evidence-based strategies offer far greater benefit than any unproven remedy, and engaging with your GP or a specialist is the most important step you can take.

Scientific References

1. Metabolic dysfunction-associated steatotic liver disease (NG49).
2. Non-alcoholic fatty liver disease (NAFLD).
3. Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults.
4. Rezdiffra | European Medicines Agency (EMA).
5. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [GID-TA11414]. In development..
6. Constipation | Treatment summaries - BNF - NICE.
7. Laxatives | Nurse Prescribers' Formulary - BNF - NICE.
8. New restrictions introduced on sales of stimulant laxatives to counter risks from overuse.
9. Alcohol consumption: advice on low risk drinking.
10. Chapter 12: alcohol – Delivering Better Oral Health.
11. Physical activity guidelines: UK Chief Medical Officers' report.
12. UK Chief Medical Officers' physical activity guidelines.
13. Physical activity guidelines for adults aged 19 to 64.
14. Effect of ricinoleic acid in acute and subchronic experimental models of inflammation. Mediators of Inflammation..
15. AGA Clinical Practice Update on the Evaluation and Management of Metabolic Dysfunction- and Alcohol-Associated Liver Disease: Expert Review. Clinical Gastroenterology and Hepatology..
16. Global epidemiological patterns and disease burden of metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease, and alcohol-associated liver disease. Clinical and Molecular Hepatology..
17. Liver donor macrosteatosis is associated with adverse long-term outcomes exclusively in metabolic dysfunction-associated steatotic liver disease recipients. Hepatobiliary Surgery and Nutrition..
18. Rapid Reversal of Liver Steatosis With Life Style Modification in Highly Motivated Liver Donors. Journal of Clinical and Experimental Hepatology..
19. Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study. Cell Reports Medicine..
20. The impact of dietary interventions on liver health biomarkers in individuals with MASLD: a systematic literature review and meta-analysis of RCTs. European Journal of Nutrition..
21. Exploring the Role of Extra Virgin Olive Oil (EVOO) in MASLD: Evidence from Human Consumption. Nutrients..
22. Structured Exercise Interventions and Hepatic-Metabolic Outcomes in Adults with MASLD: A Narrative Review of Randomized Controlled Trials. International Journal of Molecular Sciences..

Frequently Asked Questions